BI Asset Management Fondsmaeglerselskab A S Sells 241 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

BI Asset Management Fondsmaeglerselskab A S reduced its position in West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 10.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,961 shares of the medical instruments supplier’s stock after selling 241 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in West Pharmaceutical Services were worth $691,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Portside Wealth Group LLC lifted its stake in shares of West Pharmaceutical Services by 1.2% in the fourth quarter. Portside Wealth Group LLC now owns 2,675 shares of the medical instruments supplier’s stock valued at $942,000 after buying an additional 33 shares in the last quarter. Ieq Capital LLC boosted its stake in West Pharmaceutical Services by 2.4% during the 3rd quarter. Ieq Capital LLC now owns 1,478 shares of the medical instruments supplier’s stock valued at $555,000 after purchasing an additional 34 shares during the last quarter. Peninsula Asset Management Inc. raised its stake in shares of West Pharmaceutical Services by 0.4% in the fourth quarter. Peninsula Asset Management Inc. now owns 9,580 shares of the medical instruments supplier’s stock worth $3,373,000 after purchasing an additional 35 shares during the last quarter. Addison Advisors LLC lifted its holdings in shares of West Pharmaceutical Services by 37.9% in the third quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 39 shares in the last quarter. Finally, Summit Place Financial Advisors LLC boosted its position in shares of West Pharmaceutical Services by 2.5% during the third quarter. Summit Place Financial Advisors LLC now owns 1,703 shares of the medical instruments supplier’s stock valued at $639,000 after buying an additional 42 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 2,019 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $358.62, for a total value of $724,053.78. Following the completion of the sale, the vice president now directly owns 1,979 shares of the company’s stock, valued at $709,708.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CAO Chad Winters sold 815 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $358.82, for a total transaction of $292,438.30. Following the sale, the chief accounting officer now directly owns 1,309 shares in the company, valued at approximately $469,695.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Charles Witherspoon sold 2,019 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $358.62, for a total transaction of $724,053.78. Following the completion of the transaction, the vice president now owns 1,979 shares of the company’s stock, valued at $709,708.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,978 shares of company stock worth $50,852,672. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Trading Down 0.8 %

NYSE WST opened at $334.29 on Thursday. The business’s fifty day moving average is $376.22 and its 200-day moving average is $364.09. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. The stock has a market capitalization of $24.35 billion, a price-to-earnings ratio of 44.10, a PEG ratio of 5.95 and a beta of 1.05. West Pharmaceutical Services, Inc. has a one year low of $310.42 and a one year high of $415.73.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. The business had revenue of $695.40 million during the quarter, compared to the consensus estimate of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.98 earnings per share. Equities research analysts predict that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 31st will be issued a $0.20 dividend. The ex-dividend date of this dividend is Wednesday, July 31st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.24%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 10.55%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. UBS Group lowered their price target on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a research report on Friday, February 16th. StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, February 16th. KeyCorp boosted their price target on shares of West Pharmaceutical Services from $440.00 to $470.00 and gave the stock an “overweight” rating in a report on Tuesday, February 13th. Finally, Jefferies Financial Group upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their price objective for the company from $323.00 to $536.00 in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $435.20.

View Our Latest Stock Analysis on WST

West Pharmaceutical Services Company Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Stories

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.